These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35975957)

  • 1. Pharmacist Opioid Dispensing Confidence in an Evolving Practice Landscape.
    Herndon CM; Riley AM; Gattas NM; Tiemeier AM
    J Pain Palliat Care Pharmacother; 2022 Sep; 36(3):187-193. PubMed ID: 35975957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applying the capability, opportunity, motivation, and behavior model to identify opportunities to increase pharmacist comfort dispensing naloxone in Texas: A structural equation modeling approach.
    Varisco TJ; Downs CG; Rathburn KR; Fleming ML; Thornton JD
    Int J Drug Policy; 2020 Sep; 83():102827. PubMed ID: 32589581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: A national survey of community-based pharmacists.
    Hill LG; Light AE; Green TC; Burns AL; Sanaty Zadeh P; Freeman PR
    J Am Pharm Assoc (2003); 2023; 63(1):252-260.e6. PubMed ID: 36202711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Community pharmacists' preparedness to intervene with concerns around prescription opioids: findings from a nationally representative survey.
    Alvin M; Picco L; Wood P; Mnatzaganian G; Nielsen S
    Int J Clin Pharm; 2021 Apr; 43(2):411-419. PubMed ID: 32951182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Community Pharmacists' Perspectives on Dispensing Medications With the Potential for Misuse, Diversion, and Intentional Overdose: Results of a Province-Wide Survey of Community Pharmacists in Canada.
    Leong C; Alessi-Severini S; Sareen J; Enns MW; Bolton J
    Subst Use Misuse; 2016 Nov; 51(13):1724-30. PubMed ID: 27487323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
    Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
    J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacists' Perspectives on Practice, Availability, and Barriers Related to Opioids in Georgia.
    Lal A; Bai J; Basri D; Yeager KA
    Am J Hosp Palliat Care; 2019 Jun; 36(6):472-477. PubMed ID: 30522338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.
    Bailey AM; Wermeling DP
    Ann Pharmacother; 2014 May; 48(5):601-6. PubMed ID: 24523396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the RESPOND Toolkit on community pharmacists' opioid safety attitudes, self-efficacy, and knowledge.
    Irwin AN; Novak K; Alley L; Havlin T; O'Kane N; Johnston K; Hildebran C; Carson J; Hartung DM
    J Am Pharm Assoc (2003); 2020; 60(3):450-455.e3. PubMed ID: 31919007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Community pharmacist engagement in opioid use disorder prevention and treatment behaviors: A descriptive analysis.
    Salwan A; Hagemeier NE; Tudiver F; Dowling-McClay K; Foster KN; Arnold J; Alamian A; Pack RP
    J Am Pharm Assoc (2003); 2020; 60(6):e173-e178. PubMed ID: 32669219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dispensing Naloxone Without a Prescription: Survey Evaluation of Ohio Pharmacists.
    Thompson EL; Rao PSS; Hayes C; Purtill C
    J Pharm Pract; 2019 Aug; 32(4):412-421. PubMed ID: 29478362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How do patient, pharmacist and medication characteristics and prescription drug monitoring program alerts influence pharmacists' decisions to dispense opioids? A randomised controlled factorial experiment.
    Picco L; Sanfilippo P; Xia T; Lam T; Nielsen S
    Int J Drug Policy; 2022 Nov; 109():103856. PubMed ID: 36150356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Examination of why some community pharmacists do not provide 72-hour emergency prescription drugs to Medicaid patients when prior authorization is not available.
    Shepherd MD
    J Manag Care Pharm; 2013 Sep; 19(7):523-33. PubMed ID: 23964613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Community pharmacist-provided opioid intervention frequencies and barriers.
    Nichols MA; Kepley KL; Rosko KS; Hudmon KS; Curran GM; Ott CA; Snyder ME; Miller ML
    J Am Pharm Assoc (2003); 2023; 63(1):336-342. PubMed ID: 36369075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.
    Santa HM; Amirova SG; Ventricelli DJ; Downs GE; Nowalk AA; Pringle JL; Aruru M
    Am J Health Syst Pharm; 2021 Feb; 78(4):327-335. PubMed ID: 33336254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of risks associated with the prescribing and dispensing of oral anticancer medicines in Ireland.
    Hammond L; Marsden E; O'Hanlon N; King F; Henman MC; Keane C
    Int J Clin Pharm; 2012 Dec; 34(6):893-901. PubMed ID: 22961608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacist and physician satisfaction and rates of switching to preferred medications associated with an instant prior authorization program for proton pump inhibitors in the North Carolina Medicaid program.
    Jacobson Vann JC; Christofferson S; Humble CG; Wegner SE; Feaganes JR; Trygstad TK
    J Manag Care Pharm; 2010 May; 16(4):250-63. PubMed ID: 20433216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What predicts pharmacists' engagement with opioid-outcome screening? Secondary analysis from an implementation study in community pharmacy.
    Nielsen S; Sanfilippo P; Picco L; Bruno R; Kowalski M; Wood P; Larney S
    Int J Clin Pharm; 2021 Apr; 43(2):420-429. PubMed ID: 32533428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moving opioid misuse prevention upstream: A pilot study of community pharmacists screening for opioid misuse risk.
    Strand MA; Eukel H; Burck S
    Res Social Adm Pharm; 2019 Aug; 15(8):1032-1036. PubMed ID: 30031696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of naloxone access, pricing, and barriers to dispensing in Tennessee retail community pharmacies.
    Spivey CA; Wilder A; Chisholm-Burns MA; Stallworth S; Wheeler J
    J Am Pharm Assoc (2003); 2020; 60(5):694-701.e1. PubMed ID: 32146134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.